What key numbers move SIG.AX stock after the FY25 report?

Investors will focus on guidance for FY26 same-store sales, gross margin trends, and operating cash flow. For SIG.AX stock, a turnaround in operating cash flow per share from **-0.20** toward positive territory matters most for re-rating.

How does Meyka AI view SIG.AX stock valuation?

Meyka AI assigns SIG.AX a grade **B (64.64/100)** with a HOLD suggestion, noting a premium PB of **5.63** and PE **60.00**. The grade weighs sector, growth and key metrics against earnings quality.

What is the 12-month price forecast for SIG.AX stock?

Meyka AI's forecast model projects a **12-month price of A$3.86**, implying **+28.67%** upside from **A$3.00** today. Forecasts are model outputs and are not guarantees.

What are the main risks to SIG.AX stock in the near term?

Near-term risks include continued negative operating cash flow, margin pressure, and adverse policy changes for pharmacies. For SIG.AX stock, any guidance that widens the cash conversion gap will likely trigger downside.

AU Stocks

SIG.AX Sigma Healthcare (ASX) pre-market 26 Feb 2026: Earnings set price tone

ByHuzaifa Zahoor February 25, 2026February 25, 2026

SIG.AX stock opens pre-market at A$3.00 as Sigma Healthcare (ASX) prepares to publish FY25 results on 26 Feb 2026. Investors will watch revenue growth, margin trends and cash flow after reported 2025 revenue of A$6.00 billion and earnings of A$529.91 million. Early trading shows volume near 12.89M and daily range A$2.96–A$3.03, so guidance and cash conversion details should drive intraday moves and medium-term positioning.